Skip to main content
. 2021 Apr 7;76:e2420. doi: 10.6061/clinics/2021/e2420

Table 4. GRADE evidence profile.

Quality assessment Summary of findings
Number of patients Effect
No. of studies Study design Risk of bias Inconsistency Indirectness Imprecision Publication bias Bronchiectasis No bronchiectasis Relative (95%CI) Absolute (95%CI) Quality
Tuberculosis history
6 Observational study not serious seriousa not serious seriouso not found 176/573 103/827 RR 2.49 (1.65 to 3.75) 96 per 1000 ⊕○○○
Smoking history
5 Observational study not serious not serious not serious not serious not found 367/530 393/737 RR 1.25 (1.15 to 1.35) 635 per 1000 ⊕⊕○○
Pseudomonas aeruginosa infection
7 Observational study not serious not serious not serious seriouso not found 107/605 35/874 RR 4.36 (3.04 to 6.27) 28 per 1000 ⊕○○○
Purulent sputum
4 Observational study not serious seriousb not serious seriouso not found 83/229 35/285 RR 3.09 (1.68 to 5.69) 70 per 1000 ⊕○○○
Purulent mucus sputum
2 Observational study not serious not serious not serious serious o not found 57/119 17/150 RR 4.18 (2.57 to 6.79) 122 per 1000 ⊕○○○
Positive sputum culture
2 Observational study not serious not serious not serious seriouso not found 51/119 41/150 RR 1.56 (1.11 to 2.17) 284 per 1000 ⊕○○○
Admission within the past year
3 Observational study not serious not serious not serious seriouso not found 110/162 85/240 RR 1.82 (1.51 to 2.20) 222 per 1000 ⊕○○○
Daily dyspnea
2 Observational study not serious not serious not serious seriouso not found 101/119 54/150 RR 2.40 (1.91 to 3.01) 294 per 1000 ⊕○○○
Hypertension history
2 Observational study not serious not serious not serious seriouso,p not found 76/192 113/313 RR 1.10 (0.87 to 1.38) 362 per 1000 ⊕○○○
Diabetes history
2 Observational study not serious not serious not serious seriouso,p not found 40/192 50/313 RR 1.32 (0.92 to 1.90) 208 per 1000 ⊕○○○
Female
8 Observational study not serious seriousc not serious serious p not found 259/692 374/977 RR 1.09 (0.91 to 1.31) 328 per 1000 ⊕○○○
Mucous sputum
3 Observational study not serious seriousd not serious seriouso,p not found 69/172 156/189 RR 0.29 (0.05 to 1.66) 546 per 1000 ⊕○○○
Klebsiella pneumoniae infection
6 Observational study not serious not serious not serious seriouso,p not found 47/552 78/835 RR 0.92 (0.66 to 1.30) 49 per 1000 ⊕○○○
Escherichia coli infection
4 Observational study not serious not serious not serious seriouso,p not found 19/476 15/709 RR 1.92 (0.99 to 3.75) 21 per 1000 ⊕○○○
Streptococcus pneumoniae infection
4 Observational study not serious not serious not serious seriouso,p not found 7/452 11/649 RR 0.84 (0.35 to 2.05) 10 per 1000 ⊕○○○
Acinetobacter baumannii infection
3 Observational study not serious not serious not serious seriouso,p not found 12/376 24/589 RR 0.79 (0.40 to 1.55) 41 per 1000 ⊕○○○
Stenotrophomonas maltophilia infection
2 Observational study not serious not serious not serious seriouso,p not found 0/129 6/204 RR 0.23 (0.03 to 1.86) 30 per 1000 ⊕○○○
Enterobacter cloacae infection
2 Observational study not serious not serious not serious seriouso,p not found 8/333 9/499 RR 1.33 (0.52 to 3.42) 18 per 1000 ⊕○○○
Haemophilus infection
2 Observational study not serious not serious not serious seriouso,p not found 6/76 5/126 RR 1.42 (0.50 to 3.98) 69 per 1000 ⊕○○○
Anticholinergic therapy
2 Observational study not serious not serious not serious seriouso,p not found 107/140 96/142 RR 1.11 (0.96 to 1.28) 713 per 1000 ⊕○○○
FEV1/FVC
6 Observational study not serious seriouse not serious not serious not found 548 778 - SMD-0.61 (-0.89 to -0.32) ⊕○○○
FEV1%
2 Observational study not serious not serious not serious seriousq not found 119 150 - SMD-0.96 (-1.22 to -0.71) ⊕○○○
FEV1%pred
4 Observational study not serious not serious not serious not serious not found 463 692 - SMD-0.38 (-0.50 to -0.26) ⊕⊕○○
PaO2
3 Observational study not serious not serious not serious not serious not found 390 595 - SMD-0.14 (-0.27 to -0.01) ⊕⊕○○
Hospital stay
3 Observational study not serious not serious not serious not serious not found 298 468 - SMD 0.41 (0.26 to 0.56) ⊕⊕○○
Duration of symptoms
2 Observational study not serious not serious not serious seriousq not found 110 135 - SMD 0.31 (0.05 to 0.57) ⊕○○○
CRP
4 Observational study not serious serious f not serious not serious not found 385 571 - SMD 0.50 (0.07 to 0.93) ⊕○○○
WBC
4 Observational study not serious seriousg not serious not serious not found 433 685 - SMD 0.72 (0.07 to 1.36) ⊕○○○
N%
3 Observational study not serious serioush not serious not serious not found 816 1116 - SMD 0.91 (0.09 to 1.72) ⊕○○○
Smoking index (pack/year)
5 Observational study not serious seriousi not serious not serious not found 302 382 - SMD 0.72 (-0.07 to 1.50) ⊕○○○
BMI
3 Observational study not serious serious j not serious not serious not found 420 602 - SMD -0.13 (-0.37 to 0.11) ⊕○○○
Age
8 Observational study not serious seriousk not serious not serious not found 692 977 - SMD 0.15 (-0.10 to 0.39) ⊕○○○
PaCO2
3 Observational study not serious seriousl not serious not serious not found 390 595 - SMD 0.31 (-0.01 to 0.64) ⊕○○○
ESR
3 Observational study not serious seriousm not serious not serious not found 390 595 - SMD 0.53 (-0.65 to 1.72) ⊕○○○
Hb
3 Observational study not serious not serious not serious not serious not found 390 595 - SMD -0.12 (-0.25 to 0.00) ⊕⊕○○
FIB
4 Observational study not serious seriousn not serious not serious not found 463 692 - SMD 0.78 (-0.01 to 1.58) ⊕○○○
Albumin
2 Observational study not serious not serious not serious seriousq not found 130 193 - SMD -0.05 (-0.27 to 0.18) ⊕○○○

BMI, body mass index; CI, credible interval; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; FEV1/FVC, the ratio between forced expiratory volume in 1s and forced vital capacity; FEV1%, the percentage of FEV1;. FEV1%pred, FEV1 as a percentage of the predicted value; FIB, plasma fibrinogen; GRADE, grading of recommendations assessment, development, and evaluation; Hb, hemoglobin; N%, percentage of neutrophils; PaCO2, arterial carbon dioxide partial pressure; PaO2, arterial oxygen pressure; RR, risk ratio; SMD, standardized mean difference; WBC, leukocytes.

GRADE Working Group grades of evidence High quality(⊕⊕⊕⊕): Further research is unlikely to change our confidence in the estimate of effect. Moderate quality(⊕⊕⊕○): Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality(⊕⊕○○): Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality(⊕○○○): We are very uncertain about the estimate.

a. I2=61.7%; b. I2=64.1%; c. I2=59.0%; d. I2=90.9%; e. I2=81.7%; f. I2=89.0%; g. I2=95.7%; h. I2=96.9%; i. I2=95.5%; j. I2=71.1%; k. I2=81.7%; l. I2=82.5%; m. I2=98.5%; n. I2=97.3%; o. The total sample size was less than the optimal information size, p. The 95%CI of the pooled estimate included one or no effect; q. The total sample size was less than 400.